CEL SCI Corp (CVM): Operating Cash Flow
-$17.12M
Year ended 2025-09-30
-$16.75M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | -$17.12M | n/m | 2025-12-29, From 2024-10-01 |
| 2024-09-30 | -$18.81M | n/m | 2025-12-29, From 2023-10-01 |
| 2023-09-30 | -$22.85M | n/m | 2025-01-13, From 2022-10-01 |
| 2022-09-30 | -$18.24M | n/m | 2023-12-21, From 2021-10-01 |
| 2021-09-30 | -$18.79M | n/m | 2022-12-27, From 2020-10-01 |
| 2020-09-30 | -$15.28M | n/m | 2021-12-21, From 2019-10-01 |
| 2019-09-30 | -$16.32M | n/m | 2020-12-29, From 2018-10-01 |
| 2018-09-30 | -$13.39M | n/m | 2019-12-23, From 2017-10-01 |
| 2017-09-30 | -$13.79M | n/m | 2018-12-19, From 2016-10-01 |
| 2016-09-30 | -$23.08M | n/m | 2017-12-29, From 2015-10-01 |
| 2015-09-30 | -$23.83M | n/m | 2017-12-11, From 2014-10-01 |
| 2014-09-30 | -$22.93M | n/m | 2017-12-11, From 2013-10-01 |
| 2013-09-30 | -$13.55M | n/m | 2015-12-11, From 2012-10-01 |
| 2012-09-30 | -$12.19M | n/m | 2014-12-23, From 2011-10-01 |
| 2011-09-30 | -$22.56M | n/m | 2013-12-27, From 2010-10-01 |
| 2010-09-30 | -$12.80M | n/m | 2012-12-14, From 2009-10-01 |
| 2009-09-30 | -$6.51M | n/a | 2011-12-23, From 2008-10-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| CEL SCI Corp (CVM) | 2025-09-30 | -$17.12M | n/m |
| Windtree Therapeutics Inc (WINT) | 2024-12-31 | -$15.40M | n/m |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | -$4.47M | n/m |
| Pluri Inc. (PLUR) | 2026-06-30 | -$19.59M | n/m |
| IN8BIO, Inc. (INAB) | 2025-12-31 | -$12.71M | n/m |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | -$22.58M | n/m |
| Black Hawk Acquisition Corp (BKHA) | 2025-11-30 | -$650.3K | n/m |
| Jasper Therapeutics, Inc. (JSPR) | 2025-12-31 | -$77.16M | n/m |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | -$50.94M | n/m |
Compare CVM, WINT, CSBR, PLUR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗